Teladoc Health stock fell 2.65 percent as revenue stayed weak

Published on 10/04/2026 at 14:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teladoc Health stock posted USD 606.9 million in Q2 revenue, down 4 percent year over year. Analysts set a Hold consensus and USD 7.5357 target.

TDOC, US87918A1051, Illustration mit AI erstellt.

Teladoc Health stock (ISIN US87918A1051) fell 2.65 percent to USD 5.52 on the NYSE on October 2, 2026, leaving the shares 44.2 percent below the 52-week high of USD 9.89. The move keeps attention on the companys weak revenue trend and its planned insurance expansion at BetterHelp.

Revenue fell in Q2

Teladoc Health generated USD 606.9 million in second-quarter 2026 revenue, a 4 percent year-over-year decline, while adjusted EBITDA reached USD 65.7 million with a 10.8 percent margin, according to The Globe and Mail in its July 29, 2026 earnings-call transcript. The quarter also included a USD 0.21 net loss per share, compared with the USD 0.25 consensus loss cited in the same report.

The pressure was concentrated in BetterHelp. Segment revenue fell 11.6 percent year over year to USD 212.6 million, while Integrated Care revenue increased 1 percent to USD 394.3 million, according to The Globe and Mail.

Insurance shift raises execution stakes

Management guided to full-year 2026 revenue of USD 2.36 billion to USD 2.45 billion, a 5 percent midpoint reduction from the prior range, while adjusted EBITDA guidance stood at USD 271 million to USD 303 million. BetterHelp revenue guidance was USD 770 million to USD 830 million, reflecting the transition from cash-pay demand toward insurance-covered services, according to The Globe and Mail.

That mix shift creates a clear operating test: BetterHelp must convert insurance demand into paying sessions quickly enough to offset falling cash-pay revenue. The company reported 346,000 BetterHelp paying users in the quarter, down 11 percent year over year, while chronic-care enrollment rose 14 percent to 1.27 million.

Analysts see limited near term margin

MarketBeat reported on September 19, 2026, that 16 research firms carried a Hold consensus, including 10 Hold, five Buy and one Sell rating. The average 12-month price target was USD 7.5357, which lies 36.5 percent above the USD 5.52 October 2 price.

TDOC stays near yearly low

Teladoc Health stock closed at USD 5.52 on October 2, 2026, on the NYSE, with a daily range of USD 5.48 to USD 5.75 and a 52-week range of USD 4.40 to USD 9.89. Market capitalization stood at USD 1.0 billion on October 2, 2026.